Digest Network Come funziona
Network
/
Società
Co
Non verificato

Corcept Therapeutics Incorporated

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOncologiaSalute

28 comunicati stampa

Guarda tutti i comunicati
04/11/2025
Web e Social Network
Telefonia e Varie
Mercato azionario
Igiene alimentare
Biotecnologia
Salute
Medicina - Varie
Sanità
Farmaceutica
Oncologia
Corcept Therapeutics Announces Third Quarter Financial Results, Oncology Development Programs and Provides Corporate Update
Fonte
Corcept Therapeutics Incorporated
Emittente
Business Wire
1.00
0
28/10/2025
Sanità
Farmaceutica
Salute
Medicina - Varie
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call
Fonte
Corcept Therapeutics Incorporated
Emittente
Business Wire
1.00
0
19/10/2025
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Eventi
Industria
Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment
Fonte
Corcept Therapeutics Incorporated
Emittente
Business Wire
1.00
0
14/10/2025
Scienza
Medicina - Varie
Biotecnologia
Sanità
Salute
Farmaceutica
Oncologia
Industria
Corcept Submits Marketing Authorization Application to European Medicines Agency for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer
Fonte
Corcept Therapeutics Incorporated
Emittente
Business Wire
1.00
0
22/09/2025
Eventi
Fiere
Industria
Scienza
Biotecnologia
Medicina - Varie
Salute
Farmaceutica
Sanità
Oncologia
Corcept to Present New Late-Breaking Data From Pivotal ROSELLA Trial of Relacorilant in Platinum-Resistant Ovarian Cancer at ESMO 2025
Fonte
Corcept Therapeutics Incorporated
Emittente
Business Wire
1.00
0
10/09/2025
Oncologia
Igiene alimentare
Salute
Medicina - Varie
Farmaceutica
Biotecnologia
Industria
FDA Files Corcept’s New Drug Application for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer
Fonte
Corcept Therapeutics Incorporated
Emittente
Business Wire
1.00
0
31/07/2025
Attrezzature medico-sanitarie
Igiene alimentare
Medicina - Varie
Sanità
Biotecnologia
Farmaceutica
Salute
Oncologia
Web e Social Network
Telefonia e Varie
Mercato azionario
Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update
Fonte
Corcept Therapeutics Incorporated
Emittente
Business Wire
1.00
0
24/07/2025
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call
Fonte
Corcept Therapeutics Incorporated
Emittente
Business Wire
1.00
0
14/07/2025
Scienza
Biotecnologia
Farmaceutica
Oncologia
Salute
Igiene alimentare
Medicina - Varie
Industria
Corcept Submits New Drug Application for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer
Fonte
Corcept Therapeutics Incorporated
Emittente
Business Wire
1.00
0
23/06/2025
Scienza
Biotecnologia
Farmaceutica
Oncologia
Salute
Medicina - Varie
Eventi
Industria
Corcept Presents Data from Treatment Phase of CATALYST Trial at American Diabetes Association’s 85th Scientific Sessions with Simultaneous Publication in Diabetes Care
Fonte
Corcept Therapeutics Incorporated
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0